Testosterone Biotech Clarus Therapeutics Files For A $86 Million IPO

Clarus Therapeutics, a biotech awaiting FDA approval for an oral testosterone replacement therapy, filed on Friday with the SEC to raise up to $86 million in an initial public offering. The Northbrook, IL-based company, which was founded in 2003, plans to list on the NASDAQ under the symbol CLRS. Another IPO filer, Claire's (CLRS.RC), applied to list on the NYSE under the same symbol in its May 2013 filing.

Help employers find you! Check out all the jobs and post your resume.